ResearcherZhengzhou UniversityActive in the last 2 years

Yu Mu

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 7 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 2

Retraction of: Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. Co-author DOI 10.18632/aging.206242 ↗
Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. Co-author DOI 10.18632/aging.103918 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yanqiu Zhao · 1 shared paper, 2025 · strength 0.30
- Paper Retraction of: Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic canc… DOI 10.18632/aging.206242 ↗
Suxia Luo · 1 shared paper, 2025 · strength 0.30
- Paper Retraction of: Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic canc… DOI 10.18632/aging.206242 ↗
Yanqiu Zhao · 1 shared paper, 2020 · strength 0.13
- Paper Glypican-1-targeted and gemcitabine-loaded liposomes enhance tumor-suppressing effect on pancreatic cancer. DOI 10.18632/aging.103918 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.